The Effects of Renin Angiotensin System Blockage (RAS), Calcium Channel Blocker and Combined Drugs on TWEAK, PTX3 and FMD Levels in Diabetic Proteinuric Patients With Hypertension

This study has been completed.

Sponsor:

Information provided by:

Gulhane School of Medicine

ClinicalTrials.gov Identifier:

NCT00921570

First received: June 15, 2009

Last updated: June 16, 2009

Last verified: June 2009

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	May 2009
Primary Completion Date:	May 2009 (Final data collection date for primary outcome measure)

No publications provided by Gulhane School of Medicine

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Yilmaz MI, Carrero JJ, Martín-Ventura JL, Sonmez A, Saglam M, Celik T, Yaman H, Yenicesu M, Eyileten T, Moreno JA, Egido J, Blanco-Colio LM. Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation. Clin J Am Soc Nephrol. 2010 Jul;5(7):1174-81. Epub 2010 Apr 29.

To Top